Stifel Upgrades Deciphera Pharmaceuticals to Buy, Raises Price Target to $20
Portfolio Pulse from richadhand@benzinga.com
Stifel analyst Bradley Canino has upgraded Deciphera Pharmaceuticals (NASDAQ:DCPH) from Hold to Buy and raised the price target from $14 to $20.
August 10, 2023 | 9:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Deciphera Pharmaceuticals has been upgraded from Hold to Buy by Stifel, with a raised price target from $14 to $20.
The upgrade from Hold to Buy and the increase in price target by Stifel analyst Bradley Canino indicates a positive outlook for Deciphera Pharmaceuticals. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100